Reminder. Part of the RNS on 14/09/2029 Oct 2020 14:38
Additional exploratory studies will continue to understand the translation potency of the Coronavirus plasmid including optimisation of Nuvec® plasmid loading. With this in mind and taken together with previous positive data, the Company has decided to proceed to a full in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies.